# NUTRA PHARMA CORP. (NPHC) · Edgar & Edgarette company card

> Nutra Pharma (NPHC) grew revenue 4.6% in FY2025 to $0 million, operating margin -568% against a 0.7% median for medicinal chemicals & botanical products, equity -2878% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1119643 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NPHC) · [JSON](https://www.pops4.com/boards/company/NPHC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $257,612 |
| Revenue growth, 1 year | 4.6% |
| Revenue growth per year | 27.4% |
| Operating margin | -567.7% (prior year -356.6%) |
| Net margin | -794.8% |
| Operating cash flow | −$1M |
| Capital spending | $26,052 |
| Free cash flow | −$1M |
| Cash | $12,181 |
| Long-term debt | $10M |
| Total assets | $584,558 |
| Total equity | −$17M |
| Equity ÷ assets | -2878.3% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -643.06 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$1.2M in FY2025); operating loss: a margin of -567.7% in FY2025; revenue is hard to predict: its 80% range is ±66%

## Edgarette's reading

Exposure: revenue $258K (FY2025), total debt $9.8M. Experience: revenue up 4.6% on the year, up 27.4% a year over 4 years; operating margin -567.7%, down from -356.6%. Soundness: equity -2878.3% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $129K and $635K next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $115K to $712K. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -567.7% against a 0.7% median; growth 4.6% against 1.7%.

Range logged 2026-09-24, receipt bcb14962741181c2, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-Q Late quarterly report notice: 1, latest 2026-08-14 ([filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226038022/0001493152-26-038022-index.htm))

## Recent filings

- 8-K · filed 2026-09-02 · 5.01 Changes in Control of Registrant · [filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226041208/0001493152-26-041208-index.htm)
- 10-Q · filed 2026-08-19 · [filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226039166/0001493152-26-039166-index.htm)
- 10-Q · filed 2026-05-29 · [filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226026420/0001493152-26-026420-index.htm)
- 10-K · filed 2026-05-20 · [filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/0001493152-26-024641-index.htm)
- 10-Q · filed 2026-04-06 · [filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226015334/0001493152-26-015334-index.htm)
- 10-Q · filed 2026-03-25 · [filing](https://www.sec.gov/Archives/edgar/data/1119643/000149315226012625/0001493152-26-012625-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001119643.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1119643

## Cite

POPS4, Edgar & Edgarette: NUTRA PHARMA CORP. (NPHC) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/NPHC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.